Full text
Earnings transcript
Read the complete earnings call transcript.
BHC
Bausch Health Companies Inc.
$5.67
0.02
(0.35%)
| Exchange: | NYSE |
| Market Cap: | 2.121B |
| Shares Outstanding: | 89.116M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Thomas J. Appio | |||||
| Full Time Employees: | 20300 | |||||
| Address: |
| |||||
| Website: | https://www.bauschhealth.com |
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta’s medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Click to read more…
Revenue Segmentation
BHC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Bausch Health Companies, or BHC as you might know it on the ticker. Today, we’re diving deep into this player in the healthcare space to break down what makes it tick, where it’s stumbling, and what could be on the horizon for long-term investors like you. Whether you’ve been eyeing this stock or already have it in your portfolio, stick around because we’ve got a lot to unpack with a full SWOT analysis, some…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 8,757,000 | 9,625,000 | 10,266,000 |
| Gross Profit | 6,198,000 | 6,843,000 | 7,253,000 |
| EBITDA | 2,885,000 | 3,134,000 | 3,179,000 |
| Operating Income | 963,000 | 1,546,000 | 2,185,000 |
| Net Income | -592,000 | -46,000 | 157,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 27,350,000 | 26,523,000 | 26,366,000 |
| Total Liabilities | 27,432,000 | 26,845,000 | 25,989,000 |
| Total Stockholders Equity | -1,022,000 | -1,279,000 | -554,000 |
| Total Debt | 22,388,000 | 21,616,000 | 225,000 |
| Cash and Cash Equivalents | 947,000 | 1,181,000 | 1,309,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,032,000 | 1,597,000 | 1,400,000 |
| Capital Expenditure | -272,000 | -337,000 | -397,000 |
| Free Cash Flow | 760,000 | 1,260,000 | 1,003,000 |
| Net Income | -611,000 | -72,000 | 120,000 |
| Net Change in Cash | 371,000 | 239,000 | 124,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 9,979,163.674 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 10,193,365.130 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 10,113,682.440 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 4,031,956.008 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 4,086,781.842 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 4,066,385.692 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 1,312,526.253 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 1,349,298.753 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 1,335,618.753 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 3,220,460.141 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 3,289,586.901 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 3,263,871.828 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 3.560 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 3.600 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 3.500 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: BHC has demonstrated consistent revenue generation as per the latest income statements, with reported figures reflecting stability in core operations. This aligns with positive trends in the healthcare sector, particularly in pharmaceuticals, as indicated by sector performance metrics.
- Strong Free Cash Flow: The cash flow statements highlight a healthy free cash flow yield (freeCashFlowYieldTTM), indicating the company’s ability to generate cash after capital expenditures. This provides financial flexibility for reinvestment or debt management.
- Market Positioning: As part of the healthcare sector and pharmaceutical industry, BHC benefits from a stable demand environment, supported by industry performance data showing resilience across 1-year and 5-year periods compared to broader market fluctuations.
- Operational Scale: With a significant market capitalization (mktCap) and a substantial employee base (fullTimeEmployees), BHC possesses the operational capacity to execute large-scale initiatives and maintain competitive positioning within its industry.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates BHC intrinsic value between $22.55 – $50.38 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about BHC valuation
Is Bausch Health Companies Inc. (BHC) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Bausch Health Companies Inc. (BHC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BHC a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BHC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BHC’s P/E ratio?
You can see BHC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BHC?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BHC a good long-term investment?
Whether BHC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BHC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.35
Trading Metrics:
| Open: | 5.69 | Previous Close: | 5.65 | |
| Day Low: | 5.62 | Day High: | 5.73 | |
| Year Low: | 4.33 | Year High: | 8 | |
| Price Avg 50: | 5.87 | Price Avg 200: | 5.85 | |
| Volume: | 1.854M | Average Volume: | 3.096M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
